Showing results (51-60 of 55) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.The Lancet. Gastroenterology & Hepatology|October 16, 2018
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysisSami A Chadi, Lee Malcomson, Joie Ensor, et al.Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.Pageof 6